Category: Press

CNBC: Bill Smead on Health Care Stocks

Health care stocks are hated, but we’re buying them: Smead CEO By Tom DiChristopher Stocks Mentioned: MRK, PFE, AMGN For more information go to www.cnbc.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice.

⟶ Keep Reading

Modern Investor: Bill Smead on ‘The Big Long’

A-rated Smead: six reasons the US economy is the new ‘big long’ Modern Investor by Chris Sloley For more information go to www.moderninvestor.com. Stocks mentioned: JPM, WFC The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or

⟶ Keep Reading

CNBC: Bill Smead on Central Bank Policy

Central bank medicine becoming ‘poison’: Expert By Jacob Pramuk For more information go to www.cnbc.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. The securities

⟶ Keep Reading

Reuters: Tony Scherrer discusses Pfizer

Pfizer 2016 forecast disappoints By Brendan McDermid   For more information go to www.reuters.com. Stocks mentioned: PFE, AGN The information contained in this article represents Smead Capital Management’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee

⟶ Keep Reading

CNBC Squawk Box: Bill Smead on the U.S. economy

Will rate hike produce ‘collateral damage?’ Hosted by Joe Kernen and Andrew Ross Sorkin For more information go to www.cnbc.com. For the full story go to www.cnbc.com. The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or

⟶ Keep Reading

WSJ: Bill Smead on the Fed’s Interest Rate Hike

Rate Liftoff Gives a Boost to U.S. Stocks By Sarah Krouse and Katy Burne For more information go to www.wsj.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee

⟶ Keep Reading

Bloomberg: Bill Smead on Amgen’s earnings

Amgen Posts Profit That Tops Estimates, Raises Guidance By Caroline Chen & Doni Bloomfield For more information go to www.bloomberg.com. Stock’s Mentioned: AMGN The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is

⟶ Keep Reading

Reuters: Tony Scherrer discusses Pharma Earnings

Top U.S. drugmakers ride new products to strong results By Bill Berkrot and Ransdell Pierson   For more information go to www.reuters.com. Stocks mentioned: None The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice.

⟶ Keep Reading

Barron’s: Tony Scherrer discusses bio-techs

Amgen: Cheap Stock, Blockbuster Pipeline By Johanna Bennett For more information go to www.barrons.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. The securities identified

⟶ Keep Reading
Scroll to Top